Dr. Reddy’s Faces FDA Setback on AVT03 Denosumab Biosimilar After Manufacturing Inspection
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
On December 31, 2025, Dr. Reddy’s Laboratories disclosed that its wholly owned Swiss subsidiary received a Complete Response Letter from the U.S. Food and Drug Administration for the Biologics License Application for AVT03 (denosumab), a proposed biosimilar to Prolia and Xgeva developed by Alvotech. The FDA’s response is tied to observations from a pre-license inspection of Alvotech’s manufacturing facility in Reykjavik, signaling that approval of this important biosimilar candidate for the U.S. market will be delayed until the inspection issues are resolved, potentially impacting the timing of Dr. Reddy’s entry into the denosumab biosimilar space and related revenue expectations.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is an India-headquartered global pharmaceutical company engaged in the development, manufacturing and marketing of generic and branded medicines, biosimilars and active pharmaceutical ingredients. Through subsidiaries such as Dr. Reddy’s Laboratories SA in Switzerland, the company targets regulated markets including the United States, Europe and other international geographies, with a focus on complex generics and biologics to expand its footprint in key therapeutic segments.
Average Trading Volume: 1,111,672
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.79B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.
